Valuation: CSL Limited

Market Cap 41.11B 36.03B 33.3B 30.63B 57.79B 3,964B 58.72B 398B 156B 1,939B 154B 151B 6,682B P/E 2026 *
-46x
P/E 2027 * 28.6x
Enterprise Value 49.95B 43.78B 40.47B 37.22B 70.23B 4,817B 71.36B 484B 190B 2,357B 188B 183B 8,120B EV / Sales 2026 *
3.25x
EV / Sales 2027 * 3.15x
Free-Float
99.3%
Yield 2026 *
3.32%
Yield 2027 * 3.41%
1 day-0.58%
1 week-0.23%
Current month+6.86%
1 month+5.41%
3 months-10.59%
6 months-30.53%
Current year-28.98%
1 week 121.11
Extreme 121.11
124.83
1 month 110.89
Extreme 110.89
126.98
Current year 90
Extreme 90
184.62
1 year 90
Extreme 90
275.79
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 2026-02-10
Director of Finance/CFO 52 2025-10-06
Chief Operating Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 72 2018-10-16
Director/Board Member 70 2011-02-01
Director/Board Member 71 2019-12-08
Date Insider Type Main position Quantity % Market Cap.
6/1/26 Buy

Director

1,036 0.0002%
5/26/26 Buy

Chief Executive Officer

1,100 0.0002%
5/26/26 Buy

Chief Executive Officer

1,100 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-0.58%-0.23%-52.36%-53.82% 41.24B
-0.54%+2.39%+24.45%-6.10% 68.85B
-0.54%+1.02%+37.33%+189.96% 52.13B
-3.65%+34.50%+34.50%+34.50% 43.46B
-2.16%-2.94%+65.37%-26.15% 30.41B
-2.26%-8.47%+98.05%-50.84% 24.53B
-1.47%+1.14%+71.46%+80.49% 23.42B
+3.99%+3.12%+3.87%+200.81% 19.75B
+0.26%+0.39%+72.12%+126.52% 16.57B
+0.20%-2.11%+77.18%+135.79% 15.95B
Average -0.39%-1.45%+43.20%+63.12% 33.63B
Weighted average by Cap. -0.66%-0.69%+34.31%+50.06%

Financials

2026 *2027 *
Net sales 15.38B 13.48B 12.46B 11.46B 21.63B 1,483B 21.98B 149B 58.42B 726B 57.77B 56.51B 2,501B 15.62B 13.69B 12.65B 11.64B 21.96B 1,506B 22.31B 151B 59.31B 737B 58.65B 57.37B 2,539B
Net income -897M -786M -727M -669M -1.26B -86.52B -1.28B -8.69B -3.41B -42.33B -3.37B -3.3B -146B 1.18B 1.04B 960M 883M 1.67B 114B 1.69B 11.48B 4.5B 55.9B 4.45B 4.35B 193B
Net Debt 8.85B 7.75B 7.17B 6.59B 12.44B 853B 12.64B 85.71B 33.6B 417B 33.22B 32.5B 1,438B 8.06B 7.07B 6.53B 6.01B 11.34B 778B 11.52B 78.12B 30.62B 380B 30.28B 29.62B 1,311B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,904
Date Price Change Volume
26-07-20 A$122.61 -0.58% 672,117
26-07-17 A$123.32 +1.12% 1,621,401
26-07-16 A$121.95 +0.16% 1,047,549
26-07-15 A$121.75 -0.98% 907,829
26-07-14 A$122.96 +1.34% 697,252
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
85.83USD
Average target price
96.64USD
Spread / Average Target
+12.60%

Quarterly revenue - Rate of surprise